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Abstract  
B-cell receptor activation, occurring within lymph nodes, plays a key role in the pathogenesis of 
chronic lymphocytic leukemia and is linked to prognosis. As well as activation of downstream 
signaling, receptor ligation triggers internalization, transit to acidified endosomes and degradation of 
ligand-receptor complexes. In the present study we investigated the relationship between these two 
processes in normal and leukemic B-cells. We found that leukemic B-cells, particularly anergic cases 
lacking the capacity to initiate downstream signaling, internalize and accumulate ligand in acidified 
endosomes more efficiently than normal B-cells. Furthermore, ligation of either surface CD79B, a B-
cell receptor component required for downstream signaling, or surface IgM by cognate agonistic 
antibody, showed that the two molecules internalize independently of each other in leukemic but 
not normal B-cells. Since association with surface CD79B is required for surface retention of IgM, this 
suggests that uncoupling of B-cell receptor internalization from signaling may be due to dissociation 
of these two molecules in leukemic cells. Comparison of lymph node with peripheral blood cells from 
chronic lymphocytic leukemia patients showed that, despite recent B-cell receptor activation, lymph 
node B-cells expressed higher levels of surface IgM.  This surprising finding suggests that the B-cell 
receptors of lymph node and peripheral blood derived leukemic cells might be functionally distinct. 
Finally, long-term therapy with the Bruton’s tyrosine kinase inhibitors ibrutinib or acalabrutinib 
resulted in a switch to an anergic pattern of B-cell receptor function with reduced signaling capacity, 
surface IgM expression and more efficient internalization. 
Introduction  
It is now clear that signaling through the BCR plays a key role in the pathogenesis of CLL and other 
lymphomas. Several components of this pathway including: Syk,(1) Erk,(2) Akt,(3) NFAT(4) and 
NFκB(5) can be constitutively activated and drugs that target BCR signaling, such as the Bruton’s 
tyrosine kinase inhibitors (BTKi), ibrutinib and acalabrutinib, are proving extremely effective in the 
clinic.(6, 7)  BCR responsiveness varies markedly between patients with CLL and is linked to 
prognosis.(8) Some cases show features of anergy,(4, 9) a pattern that is associated with lack of 
ability to transduce a downstream signal in response to BCR ligation and the presence of markers of 
good prognosis, including low levels of CD38 and mutated immunoglobulin heavy-chain variable 
(IGHV) genes. In contrast, cases with responsive or signaling competent BCRs usually express high 
levels of CD38, have unmutated IGHV genes and a more unfavorable clinical course;(10) interestingly 
these patients tend to respond more rapidly to BCR antagonists than those with anergic BCRs. 
Although BTKi therapy is very successful in controlling CLL, it is not curative and many patients are 
left with low level residual disease, which regrows on discontinuation of drug or when resistance 
mutations develop.(11, 12) This persistent disease also suggests that, within individual patients, the 
tumor may not behave in a homogeneous manner.(13) 
Despite the central importance of BCR signaling in CLL and the efficacy of drugs that block this 
pathway, there is relatively little known about BCR dynamics in leukemic B-cells. Surface levels of 
IgM and other BCR components are generally lower in CLL compared to normal B-cells and it has 
been suggested that this might be due to a failure to properly assemble the sIg α/β subunits CD79A 
and CD79B.(14) Recent studies have shown that total IgM and CD79A levels are near normal in CLL 
but that CD79B expression, which is required for transport of BCR to the cell surface,(15) is reduced 
thus trapping IgM within the cell.(16) Exposure to IL4 increases CD79B expression and allows sIgM 
levels to increase and BCR signaling capacity to improve.(16, 17) CLL cell surface BCRs have an 
immature pattern of glycosylation that matures following ex-vivo incubation(18) or exposure to 
IL4(17) in keeping with accelerated BCR turnover induced by chronic activation. It has also been 
reported that, within the PB of individual patients with CLL, leukemic cells with the lowest sIgM 
expression show biochemical features of recent activation and proliferation, presumably because 
they have recently been released from lymphoid tissues where BCR stimulation and activation are 
thought to occur.(19, 20) Taken together, these previous data suggest that the reduced sIgM levels 
observed in CLL are due to a combination of increased turnover consequent on chronic activation 
coupled with defective transport to the cell surface resulting from a deficiency of CD79B.  
The ability of CLL BCRs to become internalized also has implications for how the tumor interacts with 
other cells, such as T-cells. We, and others, have previously shown that, as in normal LNs, activated 
CD4+ T-cells co-localize with proliferating tumor cells and, in-vitro, can supply signals that cause 
tumor proliferation.(21-24) This process normally involves endocytosis and processing of antigen 
bound to BCR, however it is not known whether CLL B-cells are capable of providing this function. In 
the present study we investigated whether, like normal B-cells, CLL cells can internalize their BCR 
and to what extent this is linked to downstream signaling in both untreated patients and those 
receiving therapy with the Bruton’s Tyrosine Kinase inhibitors ibrutinib and acalabrutinib. Our results 
shed new light on BCR function in CLL and have implications for understanding the mode of action of 
this important new class of drugs.  
Methods   
Patients and samples 
Peripheral blood (PB) samples were obtained from 19 healthy volunteers, 40 untreated patients with 
confirmed CLL (Table S1), and an additional 15 patients receiving BTKi therapy (Table S2). Lymph 
node fine needle aspirate (FNA) and paired matched PB samples were derived from 7 untreated CLL 
patients (Table S3). Ethical approval was obtained from the National Research Ethics Service 
(08/H0906/94); all patients provided informed written consent. Patients were classified as having 
unmutated IGHV genes if homology with germline was >98%(25) and as CD38+ if expression levels 
were 7% or higher (Tables S1-3).(26)  
Flow cytometry 
Cells were stained according to the manufacturer’s recommendations using fluorochrome-coupled 
antibodies (Table S4). Viable CD19+CD5+ CLL and CD19+ normal B-cells were acquired on a FACS 
Canto II flow cytometer (BD Biosciences) and analyzed using FlowJo software (TreeStar). 
 Surface (s)IgM and IgD expression was assessed using Quantum™ FITC MESF (Molecules of 
Equivalent Soluble Fluorochrome) microsphere kits and the QuickCal v. 2.3 program according to the 
manufacturer’s recommendations. Surface CD79B was quantified using R-PE MESF microsphere kits. 
BCR signaling competence was determined using the ratiometric Ca
2+
 detector Indo1-AM (Life 
Technologies) to measure intracellular calcium (Ca
2+
) levels and Ca
2+
 influx after αIgM stimulation, as 
previously described.(4, 9)   
ERK1/2 phosphorylation activation was analyzed in both treatment-naïve and BTKi-treated (collected 
before and during BTKi therapy) CLL patient B-cells. Cells were incubated with or without αIgM, or 
with phorbol 12-myristate 13-acetate (PMA; served as positive control) for 10 minutes at 37°C prior 
to intracellular and surface staining.  
B-cell receptor internalization in normal and CLL B-cells 
BCR internalization was assessed in two ways. The uptake and retention of ligand/receptor 
complexes in acidified endosomes was measured using the pH sensitive fluorescent sensor, 
pHrodo™ Red avidin (Life Technologies) linked to agonistic αIgM or IgD (pHrodo-αIgM or D). Target 
cells were incubated with either pHrodo-αIgM or D for 30 minutes at 4
o
C and then 37
o
C for 1h. 
Results are expressed as the pHrodo mean fluorescent intensity (MFI) after subtraction of the 
background signal (MFI of unlabelled anti-IgM). BCR internalization in normal and CLL B-cells was 
also directly assessed by measuring the rate of disappearance of surface (s)IgM following ligation by 
agonistic αIgM. Full methodology is provided in the supplementary information. 
Immunofluorescence Staining 
CLL B-cells were isolated using a human B-cell negative-selection kit without CD43 depletion 
(StemCell Technologies) according to the manufacturer’s instructions and purity confirmed by flow 
cytometry. Cells were labeled with pHrodo-avidin or pHrodo-αIgM, deposited onto poly-l-lysine 
coated glass slides by cytospin and stained with CytoPainter Phalloidin-iFluor 488 reagent. Images 
were acquired on a Nikon Eclipse Ti-E inverted microscope equipped with the Nikon A1R Si confocal 
imaging system. Image analysis was with Nikon Elements v4.2 software (see supplementary 
information). 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism software version 5 (GraphPad Software, 
La Jolla, CA, USA). Shapiro–Wilk test, t-test, Mann–Whitney and/or Wilcoxon’s test were used where 
indicated. P-values of <0.05 were considered significant.  
Results  
Internalization of normal and CLL BCRs. 
The uptake and retention of pHrodo-αIgM labeled BCRs in acidified endosomes was similar in 
normal and CLL B-cells (mean fluorescence intensity [MFI], ± standard deviation: normal control: 
147.5±16.8, n=19, p=0.825, CLL: 151.3±12.0, n=40; figure 1A) and correlated with sIgM expression 
(r
2
=0.405, p=0.0001, n=40; figure 1B). Confocal immunofluorescence microscopy confirmed that the 
labeled BCRs accumulate in an intracellular compartment (supplementary figure S1A) and pre-
incubation with excess unlabeled anti-IgM, sodium azide and cytochalasin-D showed the process to 
be specific and dependent on energy and the cytoskeleton (supplementary figures S1B, S1C and 
S1D). Repeated measurements confirmed the reproducibility of the assay within individual CLL cases 
(r
2
=0.874, p<0.0001, n=30; supplementary figure S1E). It has previously been reported that sIgM 
expression is lower in CLL compared to normal B-cells and this was also the case in our patients 
(figure 1C). Since BCR uptake by normal and CLL B-cells is similar and dependent on sIgM expression, 
this suggested that the process might be more efficient in CLL compared to normal B-cells. 
Correction of the pHrodo-αIgM uptake value for the number of surface IgM molecules (uptake 
index) confirmed this to be the case (figure 1D). After correcting for the level of surface IgM 
expression, the pHrodo-αIgM signal, which reflects accumulation in acidified endosomes, was 3.04 
times more efficient in CLL compared to normal B-cells (Figure 1D, p<0.0001). The uptake index 
varied considerably between patients but was significantly higher in those whose BCRs lacked the 
ability to mobilize calcium in response to BCR ligation and cases with low CD38 expression (see 
supplementary figure S2, table S1).  
Prolonged ex-vivo incubation has previously been shown to reverse features of anergy, namely, re-
expression of sIgM and restoration of BCR responsiveness.(4, 9) We therefore examined BCR 
expression and internalization after 24 hours ex-vivo incubation however results were 
heterogeneous with no significant recovery in sIgM expression (supplementary figure S3A, p=0.83, 
n=7) or change in BCR internalization efficiency (supplementary figure S3B, p=0.88, n=7). It was not 
possible to assess internalization efficiency at later time points as the assay critically depends on 
metabolic integrity of the cells, which was not consistently maintained after 24 hours.   
Since the pHrodo-αIgM signal reflects both uptake into and retention within acidic endosomes, we 
also assessed the BCR internalization rate more directly by measuring loss from the cell surface 
following ligation with agonistic antibody. This showed that all cases of CLL internalize their BCRs 
more rapidly than normal B-cells (figure 1E; p=0.04, 2 minute time point). More subtle differences 
were observed between anergic and signal competent cases of CLL with more rapid initial loss from 
the surface in the former (figure 1E; p=0.02 at 2 minute time point).  
We also measured sIgD expression and the levels of pHrodo-αIgD uptake using the same assays. All 
CLL B-cells internalized pHrodo-αIgD and pre-incubation with unlabeled αIgD reduced the level of 
uptake (supplementary figure S4A; n=18; p=0.001). No significant correlation between pHrodo-αIgD 
uptake and surface IgD expression was observed (supplementary figure S4B) and there was no 
difference in the pHrodo-αIgD uptake index between CD38hi and low, anergic/non anergic and IGHV 
mutated and unmutated patients (supplementary figures S4C). This suggests that uptake and 
retention mechanisms differ between IgD and IgM; this was not addressed further in the present 
study. 
Mechanism of dissociation of BCR signaling and internalization 
We next investigated the role of surface (s)CD79B, a molecule that is closely associated with the BCR 
and essential for signal transduction, in BCR internalization. As previously reported(27)  CLL B-cells 
express lower levels of  sCD79B compared to normal B-cells with particularly reduced expression in 
anergic compared to signaling competent cases (Normal B-cell MFI=2561.2±400.9, anergic CLL 
MFI=318.2±63.4, signaling competent MFI=397.5±71.1). We also found that sIgM expression 
correlates with sCD79B both between (figure 2A) and within a patient with CLL (figures 2B & C). 
Despite these findings and the fact that sIgM and sCD79B are known to be associated during BCR 
signaling, no significant reduction in sCD79B expression occurred following ligation and 
downregulation of sIgM with agonistic antibody in both anergic and signaling competent cases of CLL 
(figure 2D). In normal B-cells, a slight but significant reduction in sCD79B expression was observed 30 
and 60 minutes after BCR ligation with αIgM. Similarly, downregulation of CD79B with an agonistic 
anti-CD79B had no effect on the level of sIgM in anergic and signaling competent CLL cells and 
normal B-cells (figure 2E & F). Thus, although both normal and CLL B-cells are capable of internalizing 
IgM and CD79B following ligation with cognate agonistic antibody, the two molecules do not co-
internalize and thus cannot be closely associated during membrane trafficking.  
Having established that sCD79B is not required for sIgM internalization we next assessed its role in 
BCR signaling by measuring the effect of prior sCD79B downregulation on αIgM ERK phosphorylation 
in CLL cells. As expected, prior sCD79b downregulation reduced but did not abolish αIgM induced 
ERK phosphorylation (figure 2G). In contrast, depletion of sCD79B was without effect on pHrodo-
αIgM uptake (figure 2H). 
In-vivo relationship between BCR signaling and internalization 
We next investigated the relationship between BCR internalization and signaling in-vivo in CLL by 
studying subsets of peripheral blood (PB) cells, those from the lymph node (LN) where BCR 
activation and proliferation is thought to take place and longitudinal samples obtained from patients 
being treated with BTK inhibitors ibrutinib and acalabrutinib. 
Recently proliferated and quiescent subsets 
It has previously been shown that recently proliferated LN emigrant express low levels of CXCR4 and 
high levels of CD5 (CXCR4
dim
CD5
bright
).(28)  Since proliferation within LNs is linked to BCR signaling, 
we compared BCR expression and internalization efficiency on CXCR4
dim
CD5
brigh
 and CXCR4
bright
CD5
dim
 
subsets. Since the BCR internalization assay involves incubation with agonistic αIgM, we first 
investigated whether 1-hour incubation with pHrodo-αIgM altered the expression of these markers. 
As expected, CXCR4 expression was reduced and CD5 increased following ligation of BCR, however, 
over the 1h assay period, the magnitude of change was small (CXCR4 mean fold change = 0.93±0.02 
and CD5 mean fold change 1.24±0.04, data not shown). Since the MFI of the top and bottom decade 
of CXCR4 and CD5 expression differed by 11.8±5.4 and 8.7±6.7 fold respectively, assay induced 
changes could not have changed the composition of these subsets. Since the CXCR4
dim
CD5
brigh 
subset 
are thought to have recently undergone BCR activation within the LN, we expected to find 
downregulation of sIgM in this fraction, however, this was not the case and levels were higher than 
in the CXCR4
dim
CD5
brigh 
subset (figure 3A, p<0.0001). In keeping with post-activation anergy, in the 
majority of patients (14/21) there was more efficient uptake of pHrodo-αIgM in the CXCR4
dim
CD5
bright
 
subset however there was significant variability and, in the whole population, this did not reach 
statistical significance (figure 3B; n=21; p=0.281). 
BCR expression and internalization in the PB and LN of CLL patients. 
Since our results suggested that BCR internalization is influenced by the capacity to initiate 
downstream signaling, which occur within LNs, we went on to directly compare sIgM levels and 
uptake of pHrodo-αIgM by LN CLL cells to those derived from simultaneously obtained PB from the 
same patients. As we have previously shown,(29) LN CLL cells expressed higher levels of CD5 than 
those derived from the PB, in keeping with BCR activation at these sites (data not shown). As was 
the case for the recently proliferated CXCR4
dim
CD5
bright
 subset, sIgM levels were significantly higher 
on cells derived from the LN compared to PB (figure 3C; p=0.03, n=7; supplementary figure S5). 
Again, there was great variability in pHrodo-αIgM uptake efficiency with higher levels in the LN than 
PB in 5 of 7 patients, but no significant difference overall (figure 3D; p=0.218, n=7).   
BTKi-treated CLL B-cells display features of anergy  
We next investigated the effect of BCR pathway blockade on BCR expression and function. 
Peripheral blood samples were collected over time from BTKi-treated patients (ibrutinib and 
acalabrutinib) with a prolonged lymphocytosis for a minimum of 12 months (Table S2). On 
comparison of CD19+CD5+ CLL B-cells before and after 1 month of treatment, most cases showed an 
initial increase in sIgM expression (Figure 3E; p=0.02, n=7) followed by a decrease in sIgM levels after 
at least 12 months of treatment (Figure 3F; p=0.008, n=7). After 12 months or more BTKi therapy, 
CLL B-cells exhibited more efficient BCR internalization (Figure 3G; p=0.023, n=7) and had reduced 
ability to activate ERK following BCR stimulation (Figure 3H; p=0.024, n=12).  
Discussion 
In this study we investigated the capacity of normal and CLL B-cells to internalize ligands that bind to 
the BCR. Using two complementary techniques, we showed that BCR internalization and transit to 
acidified endosomes occurs in both normal and CLL B-cells. When corrected for the level of sIgM 
expression, we found that BCR internalization and accumulation in endosomes is 3 times more 
efficient in CLL than normal B-cells and is highest of all in cases with anergic BCRs. Using agonistic 
antibodies to sIgM and sCD79B we also showed that internalization of sIgM is not accompanied by 
internalization of CD79B and vice-versa. Comparison of LN with PB CLL-cells and PB 
CXCR4
dim
/CD5
bright
 cells, representing recently proliferated LN emigrants,(28) with the 
CXCR4
bright
/CD5
dim
 subset showed that both the LN and recent emigrants express higher levels of 
sIgM, however, no consistent difference in BCR internalization efficiency was observed. This was a 
surprising finding given that BCR activation takes place in the LN and should result in downregulation 
sIgM. Finally, long term in-vivo inhibition of BCR signaling using BTKis resulted in an increase in the 
number of CLL cells exhibiting features of anergy including a reduction in sIgM expression and 
signaling competence as well as an increase in the efficiency of BCR internalization.  
These results have a number of implications. First, it is clear that in CLL, BCR internalization is 
uncoupled from downstream signaling, since anergic CLL B-cells internalize their BCRs more 
efficiently than non-anergic cases and normal B-cells. These findings are in keeping with previous 
murine studies which showed that reduced surface BCR expression and uncoupling of signaling in 
normal anergic B-cells is due to rapid internalization and retention in endosomes.(30) Since 
enhanced accumulation of BCR in endosomes was observed in all patients studied, the present 
results show that, at least in this respect, all cases of CLL show some features of anergy.  
Second, although CD79B is known to associate with sIgM and is essential for export of IgM to the cell 
surface and downstream BCR signaling, our data strongly suggest that in CLL B-cells, they internalize 
independently and thus cannot be associated during endocytosis. In normal B-cells a small 
proportion of sCD79B and sIgM co-internalized, again suggesting minimal association of the two 
during endocytosis. A plausible explanation for these observations is that BCRs exist in two 
configurations in CLL (figure 4); the first in which sIgM and sCD79B are not and do not become 
associated following ligand binding and a second in which sIgM and sCD79B are already colocalized 
or are induced to associate following activation. The first configuration could not transduce 
downstream signals but, because retention of sIgM at the surface requires association with CD79B, 
would internalize efficiently. On the other hand, BCRs in which sIgM and CD79B are associated could 
initiate signaling, however, the association with CD79B would favor retention at the cell surface, at 
least until the subunits undergo phosphorylation induced dissociation.(31) Such a model has 
previously been proposed for normal B-cells(32) and is thought to favor signaling in response to low-
affinity ligands such as autoantigens of the type recognized by CLL BCRs.(33) 
It is currently believed that BCR activation takes place in LNs and that this, combined with other 
signals from the microenvironment, leads to tumor proliferation. In other receptor systems, ligand 
binding is generally accompanied by downregulation of cell-surface receptor(34) and our 
observation that sIgM levels are actually higher in the LN than PB and in recently proliferated 
CXCR4
dim
CD5
bright
 compared to CXCR4
bright
CD5
dim
 PB CLL cells was therefore unexpected. As recently 
suggested by others, it is possible that the elevated sIgM levels observed within the LN and 
CXCR4
dim
CD5
brigh
 subsets are due to IL4 induced upregulation of CD79B within lymphoid tissues.(16, 
17)   
Our findings also shed further light on the mechanism of action of BTKis. As noted by others,(13, 35) 
a persistent low-level lymphocytosis is frequently seen in such patients and complete remissions are 
rare. In the early period following the commencement of BTKi therapy, we observed an increase in 
sIgM expression in PB CLL cells. Since we have shown that cells in the LNs express higher levels of 
sIgM than those in the PB, this most likely reflects the previously documented redistribution of 
tumor from the former compartment to the later.(35) Over the longer term, however, the opposite 
is the case with a significant reduction in sIgM that is accompanied by an increase in BCR 
internalization efficiency and a reduced capacity to phosphorylate ERK. These findings indicate that 
long term BTKi therapy causes the emergence of a population of neoplastic B-cells with anergic 
phenotypic and functional properties. This may either occur through reprograming of the tumor into 
a more anergic state or because there is subclonal heterogeneity within the tumor and selection of 
cells with anergic features by BTKi therapy. The latter possibility is supported by in-vitro studies of 
leukemic B-cell migration(29) and in vivo observations using heavy water or glucose labeling(36) that 
suggest the existence of subclonal heterogeneity at a functional level in CLL. 
Finally, since BCR internalization into endosomes is the first event in antigen processing, our data 
support the theory that, under some circumstances, CLL B-cells might act as antigen presenting cells. 
We have recently show that LN derived CLL B-cells express higher levels of costimulatory molecules, 
form immune synapses and stimulate an allogeneic mixed lymphocyte reaction more efficiently than 
those from the PB.(29) In addition, elution of peptides from CLL MHC class II reveals presentation of 
a range of autologous peptides(37) with evidence for expansion of cognate T-cell clones in CLL but 
not normal PB. Furthermore, a number of groups have documented the presence of T-cells in CLL 
patients that are capable of responding to a range of other molecules including Rh antigen,(38) 
tumor idiotype(23)  immunoglobulin framework,(39) or CDR3 motifs(40) as well as broader 
responses against tumor lysates(41) or intact leukemic cells.(42) It is thus plausible that the 
abnormal phenotype, repertoire and function of CLL T-cells might be a consequence of excessive and 
aberrant antigen presentation occurring within lymphoid tissues.   
In summary, we have shown that, as in normal B-cell anergy, CLL B-cells internalize ligands that bind 
to the BCR more efficiently than normal. This process is uncoupled from downstream signaling and 
does not involve association with CD79B. We demonstrate that BTKi therapy induces or selects for 
cells with anergic properties that persist in the long term. Understanding how this occurs will be 
important in order to optimize the efficacy of this important new class of drugs.  
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Figure legends 
Figure 1: B-cell receptor expression and internalization in CLL patients and healthy controls. 
(A) PBMCs from CLL patients (n=40) and healthy controls (n=19) were incubated with pHrodo-αIgM 
and the MFI of cells internalizing pHrodo-labelled avidin was measured within the CD19+5+ (CLL) and 
CD19+ (normal) B-cell population by flow cytometry. (B) B-cell receptor (BCR) internalization 
correlates with sIgM expression (Pearson’s correlation); correlation plot comparing the relationship 
between pHrodo-αIgM uptake and surface IgM (sIgM) expression in CD19+5+ cells derived from 40 
CLL patients. (C) Although the level of pHrodo-αIgM uptake was comparable between CLL patients 
and healthy controls, marked differences in surface expression (sIgM) were observed (p=0.0001). (D) 
After correcting the level of uptake per molecule of sIgM, the uptake index was measured in both 
CLL patients and healthy controls. Within the CLL patient subsets, CLL B-cells from CD38 negative, 
anergic and mutated patients were identified as having a greater uptake index than their 
counterparts, although mutational status was not significant (p=0.05, p=0.05 and p=0.436, 
respectively; unpaired t-test). (E) To assess the rate of BCR internalization more directly, the 
disappearance of surface (s)IgM following ligation of agonistic αIgM was measured. Accelerated BCR 
endocytosis was detected (2 min time point) in anergic B-cells (n=6) compared to signaling 
competent (n=6) and normal (n=6) B-cells (p=0.02 and p=0.01, respectively*; Mann-Whitney test). 
 
Figure 2: Dissociation of BCR signaling and internalization in CLL cells.  
(A) A correlation was detected between the expression levels of surface (s)IgM and sCD79B on 
CD19
+
5
+
 cells derived from 21 CLL patients (both anergic and signaling competent B-cells, Pearson’s 
correlation). Values are expressed as molecules of equivalent soluble fluorochrome (MESF) and 
derived from mean fluorescence intensity [MFI] values). (B) To examine the relationship within an 
individual patient, fifteen subsets of CD19
+
5
+
 cells were created, as defined by increasing sIgM 
expression, and mean sCD79B MFI values were recorded within the same gate. (C) A representative 
patient demonstrating a correlation between sIgM and sCD79B. (D) The percentage of sCD79B 
receptor expression was measured on CLL and normal B-cells following agonistic αIgM ligation; a 
gradual reduction and internalization of sCD79B on normal CD19+ B-cells was detected after 60 min 
incubation (n=6; p=0.03*; Wilcoxon match pairs test). In addition, CD79B internalization (E) and sIgM 
receptor expression (F) was measured upon αCD79B ligation, and compared between anergic, 
signaling competent and normal B-cells. CD79B internalization occurred more rapidly (2 min time 
point) in anergic B-cells compared to signaling competent and normal B-cells (p=0.01 and p=0.001, 
respectively*; Mann-Whitney test), however the percentage of sIgM receptor expression remained 
unchanged in all CLL cases. Finally, signaling competent CLL B-cells were pre-incubated with agonistic 
αCD79B for 10mins at 37°C prior αIgM stimulation to determine the effect of CD79B internalization 
on αIgM-induced pERK activation (G: n=9; pERK levels were normalized to the positive control), as 
well as pHrodo-αIgM uptake (H: n=9). Statistical analysis was performed by use of Wilcoxon match 
pairs test. 
 
Figure 3: In-vivo relationship between BCR signaling and internalization in CLL cells. 
BCR expression and uptake index were investigated firstly in subsets of peripheral blood (PB) cells 
(CXCR4
bright
CD5
dim 
and CXCR4
dim
CD5
bright
 expressing CLL cells, A-B) and secondly, CD19+CD5+ cells 
from the matched lymph node (LN) and PB samples from 7 unmutated CLL patients (C-D). Thirdly, 
sIgM expression was measured in CD19+CD5+ peripheral blood (PB) cells from CLL patients before, 1 
month and at least 12 months after commencing Bruton’s tyrosine kinase inhibitor (BTKi) treatment 
(ibrutinib, n=6 or acalabrutinib, n=1; presented as a percentage change in sIgM expression, E-F). 
Uptake index (G) and the capacity to induce pERK activation following BCR stimulation (H: pERK 
levels normalized to PMA/positive control) was also examined and compared in CLL B-cells, pre- and 
during treatment. Statistical analysis was performed by use of Wilcoxon match pairs test. 
 
Figure 4. Proposed mechanism for the dissociation of BCR signaling and internalization in CLL. 
Two alternative configurations of the BCR are proposed. Type 1 in which CD79B and sIgM are 
already closely associated or become associated following ligand binding. This form of the receptor 
can transduce downstream signals but is not internalized at least until the subunits dissociate. Type 
2 BCRs do not contain CD79B either before or after ligand binding. These receptors therefore cannot 
signal but can become internalized. Possible BCR compositions in anergic and non anergic CLL are 
illustrated. In anergic CLL, both sIgM and sCD79B levels are low and there is little potential for 
association between the two either before or after ligand binding. In this scenario, downstream BCR 
signaling is minimal but internalization is efficient. In non-anergic cases of CLL, both sIgM and 
sCD79B levels are higher and there is a greater likelihood of the two to becoming associated. 
Signaling is thus relatively more efficient but the capacity for internalization is less.  
 




 Supplementary Information 
Patients and samples 
Peripheral blood mononuclear cells (PBMCs) from both CLL patients and normal healthy donors 
were isolated by density gradient centrifugation (Histopaque-1077; Sigma-Aldrich, Gillingham, UK) 
and cryopreserved in 10% dimethyl sulfoxide. Cells were thawed, washed twice and rested in RPMI 
1640 medium (Sigma-Aldrich) supplemented with 10% FBS (Sigma-Aldrich) for one hour at 37oC, 5% 
CO2 prior to each assay, unless otherwise stated. FNAs were only possible on patients with 
significant lymphadenopathy and all cases in this analysis had poor prognostic features including 
expression of CD38 and unmutated IGHV genes (Table S3). FNA was acquired from patient CLL55 
prior to commencing BTKi therapy, PB both before and during treatment.  
  
Cell surface IgM and CD79 expression 
Surface IgM and IgD (sIgM, sIgD) expression was assessed using Quantum™ FITC MESF (Molecules of 
Equivalent Soluble Fluorochrome) microsphere kits (AbD Serotec, Kidlington, UK); surface CD79B 
was quantified using R-PE MESF microsphere kits. The QuickCal v. 2.3 program 
(www.bangslabs.com) to establish a standard curve relating channel value to fluorescence intensity 
in MESF units according to the manufactures recommendations. Identical cytometer settings were 
used for the CLL patient and control samples. PBMCs (5x105 cells) were incubated with anti-CD19-
PB, anti-CD5-APC (both Biolegend) and either Fluorescein isothiocyanate (FITC)-conjugated anti-
human sIgM/D or FITC-conjugated isotype control (both eBioscience) on ice, washed and prepared 
for flow cytometry. Approximately 5000-10000 events from gated, viable B-cells from CLL patients 
(CD19+/CD5+) and normal B-cells (CD19+) were collected and analyzed as described above. sIgM/D 
and isotype control median fluorescence intensity (channel values) was converted into MESF values 
 using the online QuickCal program. Finally sIgM/D MESF was normalized to isotype control MESF to 
assign the definitive MESF value.   
 
Calcium mobilization assay  
Briefly, 5 x 106 cells/ml CLL PBMCs were incubated in media supplemented with 1 μM Indo1-AM for 
1 h at 37°C, then washed and re-suspended in fresh medium and incubated at 37°C for 30 minutes 
then stored on ice before being used for experiments. For each acquisition, 3 x 106 PBMCs re-
suspended in 1 ml of medium were used. For dead cell exclusion 5 µl of the 7-AAD Viability Staining 
Solution (Biolegend) was added to each sample and incubated for 10 minutes in the dark before data 
acquisition; cells were warmed to 37°C for 5 minutes before performing the analysis. Background or 
basal Ca2+ fluorescence was recorded followed by addition of goat F(ab’)2 anti-human IgM (20 μg / 
ml; Cambridge Biosciences) and events were recorded up to 300 seconds. Ionomycin at a 
concentration of 1 μM was used to produce calcium flux as a positive control. Flow cytometric data 
were acquired using FACS Diva software and analyzed using the kinetic application of the FlowJo 
software (Tree Star, Inc.). Background fluorescence threshold intensity was established at the 85th 
percentile of basal fluorescence of unstimulated cells, as previously described. The percentage of 
cells responding to anti-human IgM stimulation was calculated and patients were classified as signal 
competent/non-anergic when the percentage of responding cells was greater than 5% or non-signal 
competent/anergic if responding cells were below 5% (supplementary Figure S2). 
 
Phospho-flow cytometry 
ERK1/2 phosphorylation activation was analyzed by ﬂow cytometry in viable CD19+CD5+ CLL 
according to the manufactures protocol. In summary PBMCs from CLL patients were incubated with 
or without unlabeled F(ab’)2 αIgM for 10 minutes at 37°C, washed and fixed in pre-warmed fixation 
 buffer (Biolegend UK) for 15 minutes at 37°C. In independent experiments a pre-incubation step 
with agonistic αCD79B for 10mins at 37°C was included prior to αIgM stimulation to establish 
whether CLL B-cells that have undergone CD79B endocytosis can still signal via the BCR. Cells were 
then washed and permeabilized with pre-chilled True-Phos™ Perm Buffer (Biolegend UK) for 60 
minutes at -20°C, washed and stained with anti-CD19, CD5 and pERK1/2 for 30 minutes at room 
temperature. Data were acquired and analyzed by flow cytometry. Cells stimulated with phorbol 12-
myristate 13-acetate (PMA) for 10 minutes at 37°C served as positive control; ERK1/2 
phosphorylation levels of untreated (baseline) and αIgM-treated (activated) B-cells were normalized 
to the positive control. 
 
B-cell receptor internalization 
BCR internalization was assessed in two ways. First, we used the pH sensitive fluorescent sensor, 
pHrodo™ Red avidin (Life Technologies, Paisley, UK) linked to agonistic anti-IgM or IgD (pHrodo-αIgM 
or D) to detect uptake and retention of ligand/receptor complexes in acidified endosomes. The 
fluorogenic dye-avidin conjugate is non-fluorescent outside the cell at a neutral pH but dramatically 
increases in fluorescence as the pH of its surroundings becomes more acidic. One microgram of 
pHrodo™ Red Avidin was incubated with an equimolar amount of biotinylated goat F(ab’)2 anti-
human Immunoglobulin M or D (αIgM or IgD; Cambridge Biosciences, Cambridge, UK) for 1h at room 
temperature. Target cells were incubated with either pHrodo-avidin-αIgM (pHrodo-αIgM or D) for 30 
minutes at 4oC and then 37oC for 1h and stained with viability dye, anti-CD19, CD5 and CXCR4, 
according to the manufactures recommendations; data were acquired on a FACS Canto II flow 
cytometer (Becton Dickinson, Oxford, UK) and analyzed using FlowJo software (Tree Star; Ashland, 
OR, USA); approximately 5000-10000 events were collected from each sample gated on live cells, 
expressing CD19 and CD5 (CD19+/CD5+). All incubations were performed in PBS pH 7.4, so that any 
observed fluorescence was due to BCR internalization and trafficking of the pHrodo-αIgM to 
 acidified endosomes. Results are expressed as the pHrodo mean fluorescent intensity (MFI) after 
subtraction of the background signal (MFI of unlabelled anti-IgM). 
To confirm BCR specificity, experiments were performed in the presence of a molar excess of 
unlabeled αIgM or D (Cambridge Biosciences). To investigate energy dependence and the role of the 
cytoskeleton, cells were pre-incubated with either sodium azide (0.2%; Severn Biotech Ltd, 
Kidderminster, UK) or cytochalasin D (10µM; Sigma-Aldrich) for 1h at 37oC. In addition, a pre-
incubation with agonistic αCD79B for 10mins at 37oC was included to specific experiments prior to 
αIgM stimulation, to assess the effect of CD79B endocytosis on BCR internalization in CLL B-cells. 
Second, BCR internalization was also assessed directly by measuring the rate of disappearance of 
surface IgM following ligation by agonistic anti-IgM over the same duration of time as the pHrodo-
αIgM uptake assay. As described above, normal and CLL PBMCs (5x105/tube) were incubated with  
biotinylated αIgM for 30 minutes at 4oC to allow initial receptor binding, washed twice with ice cold 
PBS, then incubated at 37oC for the time indicated (0, 2, 5, 10, 30, and 60 min) to allow receptor 
endocytosis. The cells were then washed twice with ice cold PBS and stained with CD79B FITC and 
streptavidin (SAV)-APC, in addition to viability dye, CD19 PB and CD5 PE-Cy7 in PBS for 30 minutes 
on ice. CD79B internalization was also assessed following ligation by agonistic biotinylated αCD79. 
Here, cells were washed and stained with anti-CD19, CD5, IgM and streptavidin (SAV)-APC. Cells 
were then washed twice and fixed in PBS 1% paraformaldehyde (PFA) before FACS acquisition. 
Maximal fluorescence (Fmax) was defined as the APC fluorescence at 4oC which represents the 
starting amount of αIgM-APC bound to the cells without endocytosis (0 minutes at 37oC). APC mean 
MFI was recorded at each time point (Ftp). The rate of BCR internalization or disappearance was 
calculated and defined as the percentage surface BCR expressed or remaining (following 
internalization) using the following formula: Ftp/Fmax x100. 
 
Immunofluorescence Staining 
 B-cells from CLL patients and healthy controls were isolated using a human B-cell negative-selection 
kit without CD43 depletion (StemCell Technologies, Grenoble, France), according to the 
manufacturer’s instructions. Briefly, 5x105 purified cells were incubated with pHrodo-avidin or 
pHrodo-αIgM as above, washed and re-suspended in 150µl of cell culture media (supplemented with 
20% FBS) and deposited onto poly-l-lysine coated glass slides by cytospin (300x g for 5 minutes). 
Slides were fixed with 1% PFA for 15 minutes at room temperature, washed 3 times in PBS and 
permeabilized in 0.5% Triton/PBS for 10 minutes. The slides were washed again 3 times and stained 
with CytoPainter Phalloidin-iFluor 488 reagent (1:1000 PBS with 1% BSA; Abcam, Cambridge, UK) for 
30 minutes, then washed and stained with 100µl of water-based mounting medium (Life 
Technologies). Images were acquired on a Nikon Eclipse Ti-E inverted microscope equipped with the 
Nikon A1R Si confocal imaging system. Image analysis was with Nikon Elements v4.2 software. 
  
 
 
 
 
 
 
 
 
 
 
 Supplementary Figures 
Figure S1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. BCR-pHrodo-αIgM internalization: intra-patient variability and specificity in CLL B-cells 
(A) A representative image of B-cells from an unmutated CLL patient post-internalization of pHrodo-
αIgM. CLL B-cells were selected from PBMCs (negative selection) and incubated with control 
(pHrodo-avidin) or pHrodo avidin conjugated to biotinylated F(ab’)2 anti-IgM (pHrodo-αIgM; red) for 
the time specified. Cells were fixed and stained with phalloidin (green) and evaluated by 
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 immunofluorescence (original magnification, X100). The effect of unlabeled F(ab’)2 anti-IgM (UNLAB-
αIgM; n=9; B), cytochalasin D (cyto D; n=9; C) and sodium azide (n=9; D) on BCR-pHrodo-αIgM 
internalization in CLL patients was determined. CLL cells were pre-incubated for the times specified 
prior to pHrodo-αIgM incubation. Internalization was measured by flow cytometry and mean 
fluorescence intensity (MFI) values recorded. Statistical analysis was performed by use of paired t-
test. (E) A correlation plot measuring experimental reproducibility within each individual CLL case 
(Pearson’s correlation). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure S2. 
 
Figure S2. Determining sIgM-mediated signaling responses in CLL patients. 
Leukemic cells from 26 patients were labeled with the calcium-sensitive dye, Indo1-AM, and 
analyzed by flow cytometry before and after addition of F(ab′)2 anti-IgM. (A) Representative trace 
measuring intracellular calcium levels before and after (indicated by arrow) BCR ligation with 
unlabeled F(ab′)2 anti-IgM in two CLL patients. CLL37 was identified as signaling competent, due to 
detection of increased intracellular calcium levels above baseline or unstimulated threshold (>5% of 
cells were able to increase the calcium-associated fluorescence following BCR stimulation). CLL3 was 
unresponsive to anti-IgM stimulus, and was therefore considered a non-signaler, or anergic. Both 
 patients produced a complete response when the non-specific stimulant, ionomycin was added to 
cell culture (indicated by arrow). (B) CD38 status and calcium flux. Leukemic cells were grouped on 
the basis of CD38 status, a marker with prognostic impact. Mean calcium flux was lower in CD38 
negative (-ve) than CD38 positive (+ve) CLL B-cells (mean % responding cells: CD38-ve = 9.5±6.7, 
CD38+ve = 15.1±2.9; p=0.01), with 9/11 CD38-ve patient samples below the threshold cut off and 
BCRs deemed unresponsive (no statistical difference in mean % responding cells was detected 
between mutated and unmutated CLL B-cells; p=0.06, data not shown). Graph shows individual data 
point and means (horizontal line). Data were analyzed by using Mann-Whitney U test (P value is 
indicated). 
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Figure S3. CLL B-cells maintain features of anergy following 24h in-vitro culture.  
CLL B-cells (n=7 patients) were incubated for 1 hour or cultured for 24 hours in media prior to 
measuring sIgM expression (A) and BCR internalization efficiency (B; uptake index). Data were 
analyzed using the Wilcoxon match pairs test. 
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Figure S4. Levels of IgD expression and internalization do not correlate with prognostic factors in 
CLL. 
The effect of unlabeled unlabeled αIgD on the levels of pHrodo-αIgD uptake in CLL B-cells was 
determined (n=18). PBMCs from CLL patients were pre-incubated for the times specified prior to 
pHrodo-αIgD incubation. Internalization was measured within the CD19+5+ B-cell population by flow 
cytometry and mean fluorescence intensity (MFI) values recorded. (B) Correlation plot exploring the 
p =0.001 
A 
p = 0.903 
r
2
 = 0.001 
B 
C 
To
ta
l C
LL
C
D
38
 -v
e
C
D
38
 +
ve
M
ut
at
ed
U
nm
ut
at
ed
A
ne
rg
ic
S
ig
na
lli
ng
 c
om
pe
te
nt
0.0
0.2
0.4
0.6
U
p
ta
k
e
 I
n
d
e
x
p = 0.5 p = 0.8 p = 0.8 
 relationship between pHrodo-αIgD uptake and surface IgD (sIgD) expression. (C) Comparing the 
pHrodo-αIgD uptake index between subgroups that determine good or poor prognosis. Statistical 
analysis was performed by use of unpaired T-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure S5. 
 
Figure S5. Comparing sIgM expression in matched PB and LN CLL B-cells. 
(A) Representative contour plots showing matched PB and LN CD19+CD5+ (circled) CLL cells from a 
single patient (CLL55). (B) The gated CD19+CD5+ cells were co-stained with sIgM FITC and presented 
as a histogram of fluorescence intensity.  
 
 
 Supplementary Tables 
Table S1: Characteristics and clinical features of CLL patients 
PATIENT 
 ID 
GENDER  (M/F) 
/ AGE (YEARS) 
CD38 (%) 
EXPRESSION 
(1) 
IGVH  
STATUS 
(2) FISH 
BINET 
STAGE 
SIGNALING 
COMPETENT BCR 
(3) 
CLL1 F / 74 0 MUTATED Normal A N 
CLL2 M / 62 1 MUTATED Negative for 11q and 17p A N 
CLL3 F / NA 2 MUTATED NA A N 
CLL4 M / 80 3 MUTATED TP53 - , 13q - A Y 
CLL5 M / 73 3 MUTATED Negative for 11q and 17p A Y 
CLL6 M / 53 3 MUTATED 13q- B N 
CLL7 F / 53 3 MUTATED Negative for 11q and 17p A NA 
CLL8 F / 35 4 MUTATED Normal A N 
CLL9 F / 71 5 MUTATED NA A N 
CLL10 F / 49 6 MUTATED Normal A N 
CLL11 M / NA 10 MUTATED 13q- A NA 
CLL12 M / NA 15 MUTATED 13q- C N 
CLL13 M / 66 18 MUTATED 13q- B NA 
CLL14 F / 64 36 MUTATED NA A NA 
CLL15 M / 60 42 MUTATED 13q- , Partial deletion of IGH A Y 
CLL16 F / 63 44 MUTATED 13q- A NA 
CLL17 M / 69 49 MUTATED deletion of one copy of IGH 
variable region A NA 
CLL18 M / 54 77 MUTATED 13q- A NA 
CLL19 M / NA 88 MUTATED 13q- , ATM - B NA 
CLL20 M / 68 91 MUTATED 13q- C N 
CLL21 F / 67 1 UNMUTATED 13q-  , TP53 - A N 
CLL22 M / 84 5 UNMUTATED 
13q- , Trisomy 12 
Loss of one copy of IGH@ variable 
region 
B N 
CLL23 NA / 59 15 UNMUTATED 11q - NA Y 
CLL24 F / 72 16 UNMUTATED TP53 - B Y 
CLL25 M / 46 18 UNMUTATED 
deletion of both copies  of IGH@ 
variable region 
NA Y 
CLL26 M / 58 19 UNMUTATED 13q- C NA 
CLL27 M / 33 19 UNMUTATED Normal A NA 
CLL28 M / 52 23 UNMUTATED 
13q- , TP53 - 
deletion of one copy  of IGH@ 
variable region 
B Y 
CLL29 F / NA 30 UNMUTATED ATM - B NA 
CLL30 F / 39 34 UNMUTATED Normal B NA 
CLL31 M / 50 51 UNMUTATED Loss of IGH@ variable region, ATM - B Y 
CLL32 M / 75 57 UNMUTATED deletion of one copy  of IGH@ variable 
region C Y 
CLL33 M / 68 61 UNMUTATED 
13q- , ATM -, deletion of both copies  of 
IGH variable region 
B N 
CLL34 M / 74 66 UNMUTATED 13q - , TP53 - B NA 
CLL35 M / 75 83 UNMUTATED Trisomy12 C Y 
CLL36 M / 74 84 UNMUTATED 13q - , 11q - C Y 
CLL37 F / 75 94 UNMUTATED Trisomy12, 13q- , ATM -, TP53 - C Y 
 CLL38 M / 66 97 UNMUTATED Normal B Y 
CLL39 M / 64 98 UNMUTATED Trisomy12, ATM - C NA 
CLL40 F / 52 99 UNMUTATED Trisomy12, partial deletion of IGH@ 
variable region A Y 
 
(1) CD38 positive (+) indicates ≥7% of CLL cells express CD38 above control. 
(2) Unmutated indicates <2% change in IGVH gene sequence compared to germline. 
(3) BCR signaling responses are analysed by calcium mobilization. The percentage of cells responding 
to anti-human IgM stimulation was calculated and patients were classified as signal competent/ non 
anergic when the percentage of responding cells was greater than the 5% (Y) or non-signal 
competent/ anergic if responding cells were below the 5% cut off (N). 
NA, not available;   - , deletion; M, Male; F, Female. 
 
 
 
 
 
 
 
 
 
 
 Table S2: Characteristics and clinical features of CLL patient undergoing ibrutinib or acalabrutinib 
treatment. 
PATIENT 
ID 
GENDER  (M/F)  
/ AGE (YEARS) 
IBRUTINIB / 
ACALABRUTINIB 
TREATMENT 
DURATION 
OF 
TREATMENT 
(MONTHS) 
CD38 (%)  
EXPRESSION 
(1) 
IGVH  
STATUS 
(2) FISH 
BINET 
STAGE 
CLL41 F / 58 IBRUTINIB 17.0 0 MUTATED 13q -  C 
CLL42 M / 84 IBRUTINIB 30.3 5 UNMUTATED 
13q- , Trisomy 12 
Loss of one copy of 
IGH@ variable 
region  
B 
CLL43 M /  59 ACALABRUTINIB 17 30 NA Trisomy 12 C 
CLL44 F / 59 IBRUTINIB 26 7 UNMUTATED 
13q- , Trisomy 12 
Loss of one copy of 
IGH@ variable 
region  
B 
CLL45 M /  63 IBRUTINIB 31 1 MUTATED 11q -  B 
CLL46 M / 61 IBRUTINIB 36 37 MUTATED 13q -  C 
CLL47 M / 57 IBRUTINIB 25 6 MUTATED 
13q- , Loss of one 
copy of IGH@ 
variable region  
C 
CLL48 F / 71 IBRUTINIB 12 2 MUTATED 17p - , Trisomy 12 B 
CLL49 NA / 61 IBRUTINIB 12 17 NA 17p -  C 
CLL50 NA / 61 IBRUTINIB 12 59 UNMUTATED Trisomy 12 B 
CLL51 F / 68 IBRUTINIB 12 4 NA 11q - , Trisomy 12 C 
CLL52 M / 67 IBRUTINIB 13 86 MUTATED 13q -  C 
CLL53 M / 57 ACALABRUTINIB 22 2 UNMUTATED 13q - , 17p - A 
CLL54 NA / 55 ACALABRUTINIB 20 75 UNMUTATED 17p - , Trisomy 12 C 
CLL55 M / 51 IBRUTINIB 12 31 UNMUTATED ATM - , Trisomy12 Relapsed 
disease 
(1) CD38 positive (+) indicates ≥7% of CLL cells express CD38 above control. 
(2) Unmutated indicates <2% change in IGVH gene sequence compared to germline. 
NA, not available;   - , deletion; M, Male; F, Female. 
 Table S3: Characteristics and clinical features of CLL patient samples used for matched LN and PB 
experiments. 
PATIENT ID GENDER  (M/F)  
/ AGE (YEARS) 
CD38 (%)  
EXPRESSION 
(1) IGVH STATUS 
(2) FISH BINET 
STAGE 
CLL55 M / 51 31 UNMUTATED ATM -  , Trisomy12 Relapsed 
disease 
CLL56 M / 58 5 UNMUTATED 13q-  C 
CLL57 M / 62 78 UNMUTATED ATM -  , 13q -  B 
CLL58 M / 56 50 UNMUTATED 13q -  B 
CLL59 F / 65 85 UNMUTATED 13q -  B 
CLL60 M / 70 9 UNMUTATED 13q -  A 
CLL61 M / 65 8 NA TP53 - , 13q - C 
(1) CD38 positive (+) indicates ≥7% of CLL cells express CD38 above control. 
(2) Unmutated indicates <2% change in IGVH gene sequence compared to germline. 
NA, not available;   - , deletion; M, Male; F, Female. 
 
 
 
 
 
 
 
 Table S4: Flow cytometry antibody list 
ANTIBODY/DYE FLUOROCHROME / LABEL CLONE ISOTYPE COMPANY 
CD5 APC UCHT2 Mouse IgG1, κ Biolegend 
CD5 PE-CY7 UCHT2 Mouse IgG1, κ Biolegend 
CD19 PB HIB19 Mouse IgG1, κ Biolegend 
CD79B PE CB3-1  Mouse IgG1, κ Biolegend 
CXCR4 APC 12G5 Mouse IgG2a, κ Biolegend 
anti-ERK1/2 
Phospho 
(Thr202/Tyr204) 
PE 6B8B69 Mouse IgG2a, κ Biolegend 
sIgM FITC SA-DA4  Mouse IgG1, κ eBiosciences 
sIgD FITC IA6-2 Mouse IgG2a, κ Biolegend 
αIgM Biotin - - SouthernBiotech 
αIgD Biotin - - SouthernBiotech 
αCD79B Biotin SN8 Mouse IgG1, κ Ancell 
Streptavidin APC - - Biolegend 
Fixable viability 
dye efluor780 - - eBiosciences 
Viability staining 
solution 7AAD - - Biolegend 
 
 
